<DOC>
	<DOC>NCT00814125</DOC>
	<brief_summary>To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.</brief_summary>
	<brief_title>ATAC - Endometrial Sub-Protocol</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients eligible for entry into the main ATAC trial (1033IL/0029) Not received any previous tamoxifen, for whatever reason Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years No previous endometrial ablation Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Endometrial</keyword>
	<keyword>Endometrial histological findings</keyword>
</DOC>